Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep model.
CytoSorb
adsorption
blood purification
hemoadsorption
hemoperfusion
immunosuppressant drugs
immunosuppressants
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
07
2023
accepted:
02
10
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Hemoadsorption shows promising signals in organ preservation and post lung transplantation. However, its potential impact on the pharmacokinetics of immunosuppressant drugs (ID) is still unknown. In this interventional study, CytoSorb® hemoperfusion was tested in healthy sheep ( Negligible clearance was observed for PRED and BAS. For all other substances, a saturable adsorption sub-model with linear decrease of the adsorption effect over the adsorbed amount best described the measured concentrations. The maximum absolute adsorbed amounts (95% CI) for TAC, CYA, MMF, EVER, and MP were 0.040 (0.028-0.053), 1.15 (0.39-1.91), 4.17 (2.00-6.35), 0.0163 (0.007-0.026), and 53.4 mg (20.9-85.9), respectively, indicating an adsorption of less than 5% of the daily administered dosages for all investigated substances. In this large animal model, CytoSorb® hemoperfusion appears to have a limited effect on the clearance of tested ID.
Identifiants
pubmed: 37928476
doi: 10.3389/fmed.2023.1258661
pmc: PMC10623319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1258661Informations de copyright
Copyright © 2023 Leber, Liebchen, Rohrhofer, Weber, Klaus, Scheier, Sucher and Stiegler.
Déclaration de conflit d'intérêts
TK and JS are full-time employees of CytoSorbents Europe GmbH. UL has received fees for consulting activities from CytoSorbents Europe GmbH. BL and PS have received research grants from CytoSorbents Europe GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Artif Organs. 2017 Jul 5;40(7):358-360
pubmed: 28574114
PLoS One. 2013 Nov 22;8(11):e81300
pubmed: 24278415
Intensive Care Med. 2019 Feb;45(2):236-239
pubmed: 30446798
Cell Mol Immunol. 2017 Feb;14(2):146-179
pubmed: 27721455
Sci Rep. 2021 May 18;11(1):10493
pubmed: 34006946
Nat Commun. 2022 Jul 26;13(1):4173
pubmed: 35882835
Intensive Care Med Exp. 2018 May 4;6(1):12
pubmed: 29728790
Hum Reprod. 2011 Nov;26(11):3028-36
pubmed: 21896546
Am J Transplant. 2017 Sep;17(9):2363-2371
pubmed: 28141897
Am J Transplant. 2004 Apr;4(4):626-35
pubmed: 15023156
Nefrologia (Engl Ed). 2019 Sep - Oct;39(5):506-512
pubmed: 30850218
Ann Thorac Cardiovasc Surg. 2022 Jun 20;28(3):186-192
pubmed: 35046210
Clin Transplant. 2018 Apr;32(4):e13211
pubmed: 29377282
Eur J Cardiothorac Surg. 2022 Dec 2;63(1):
pubmed: 36214633
Crit Care Med. 2008 Jan;36(1):268-72
pubmed: 18090355
Vet Clin North Am Small Anim Pract. 2011 Jan;41(1):227-38
pubmed: 21251519
J Thorac Dis. 2018 Mar;10(Suppl 5):S629-S641
pubmed: 29732181
Curr Pharm Des. 2020;26(28):3385-3388
pubmed: 32600225
Blood Purif. 2002;20(4):380-8
pubmed: 12169849
Crit Care Explor. 2022 May 09;4(5):e0688
pubmed: 35783552
Sci Rep. 2021 May 13;11(1):10190
pubmed: 33986443
Crit Care. 2021 Jan 28;25(1):41
pubmed: 33509234
Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96
pubmed: 33332922
Biomedicines. 2021 Jul 01;9(7):
pubmed: 34356830
J R Soc Med. 2009 Mar;102(3):120-2
pubmed: 19297654
Pharmacotherapy. 2021 Jan;41(1):119-131
pubmed: 33131123
J Heart Lung Transplant. 2017 May 20;:
pubmed: 28587802
J Thorac Cardiovasc Surg. 2021 Feb;161(2):e109-e121
pubmed: 32201002
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):348-361
pubmed: 35020971
Transplant Rev (Orlando). 2021 Apr;35(2):100585
pubmed: 33071161
Clin Pharmacokinet. 2008;47(7):449-62
pubmed: 18563954
J Card Surg. 2020 Apr;35(4):940-941
pubmed: 32101624